rs1260326
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We evaluated, in a general French population, the contribution of the GCKR rs1260326-P446L polymorphism to quantitative metabolic parameters and to dyslipidemia and hyperglycemia risk.
|
18556336 |
2008 |
rs1260326
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A polymorphism in the GCKR gene predicted dyslipidaemia (rs1260326, OR 1.15, 95% CI 1.09-1.22, p < 0.00001) but not the metabolic syndrome.
|
18853134 |
2008 |
rs1260326
|
|
|
0.030 |
GeneticVariation |
BEFREE |
There were significant associations between rs1260333 (OR is 0.82, 95 % CI 0.74-0.92, p ~ 3.96 × 10(-4)), rs1260326 (OR is 0.82, 95 % CI 0.74-0.92, p ~ 5.31 × 10(-4)), and rs964184 (OR is 1.36, 95 % CI 1.20-1.55, p ~ 1.89 × 10(-6)) and dyslipidemia.
|
23832694 |
2013 |
rs780094
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results of this population-based study provide evidence for a relationship between lipid regulatory gene polymorphisms including GCKR (rs780094), GCKR (rs1260333), FADS (rs174547), and MLXIPL (rs3812316) with dyslipidemia in an Iranian population.
|
29858861 |
2018 |
rs780094
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Consistent with observations in white Europeans, the GCKR rs780094 polymorphism contributes to the risk of type 2 diabetes and dyslipidaemia in Han Chinese individuals.
|
19241058 |
2009 |
rs780094
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The minor GCKR A-allele of rs780094 is associated with an increased level of fasting serum triacylglycerol (p = 6 x 10(-14)), impaired fasting (p = 0.001) and OGTT-related insulin release (p = 3 x 10(-6)), reduced homeostasis model assessment of insulin resistance (p = 0.0004), WHO-defined dyslipidaemia (p = 6 x 10(-9)) and a modestly decreased risk of type 2 diabetes (p = 0.01).
|
18008060 |
2008 |
rs780092
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We aimed to investigate associations of rs780092 with incident type 2 diabetes and dyslipidaemia, and the longitudinal changes in glucose and lipid levels.
|
26515422 |
2016 |